These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35513231)

  • 1. Time-averaged DAS28 and HAQ predict cardiovascular disease in patients with rheumatoid arthritis: Data from KORONA registry.
    Min HK; Kim HR; Lee SH; Kang KY; Park SH; Kwok SK
    Joint Bone Spine; 2022 Oct; 89(5):105401. PubMed ID: 35513231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline bony erosions and time-averaged DAS28 predict discontinuation of TNF inhibitors in rheumatoid arthritis.
    Min HK; Kim SH; Lee SH; Kim HR
    Sci Rep; 2022 Nov; 12(1):19951. PubMed ID: 36402804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study.
    Arts EE; Fransen J; Den Broeder AA; van Riel PLCM; Popa CD
    Ann Rheum Dis; 2017 Oct; 76(10):1693-1699. PubMed ID: 28606965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in clinical characteristics and their influence on clinical outcomes in an observational cohort of patients with rheumatoid arthritis.
    Shin S; Park EH; Kang EH; Lee YJ; Song YW; Ha YJ
    Joint Bone Spine; 2021 May; 88(3):105124. PubMed ID: 33346105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation.
    Kumar BS; Suneetha P; Mohan A; Kumar DP; Sarma KVS
    Indian J Med Res; 2017 Nov; 146(Supplement):S57-S62. PubMed ID: 29578196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients.
    Arts EE; Fransen J; den Broeder AA; Popa CD; van Riel PL
    Ann Rheum Dis; 2015 Jun; 74(6):998-1003. PubMed ID: 24458537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.
    Pan Y; Norton S; Gwinnutt JM; Kearsley-Fleet L; Symmons DPM; Lunt M; Young A; ; Hyrich KL; Verstappen SMM
    PLoS One; 2019; 14(5):e0215999. PubMed ID: 31107887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register.
    Twigg S; Hensor EMA; Emery P; Tennant A; Morgan AW;
    J Rheumatol; 2017 Sep; 44(9):1331-1340. PubMed ID: 28668806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
    Morris NT; Brook J; Ben-Artzi A; Martin W; Kermani TA; Avedikian-Tatosyan L; Karpouzas G; Nagam H; Navarro G; Choi S; Taylor MB; Elashoff D; Kaeley GS; Ranganath VK
    Clin Rheumatol; 2021 Dec; 40(12):5055-5065. PubMed ID: 34269927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
    Fanouriakis A; Papalopoulos I; Gergianaki I; Spyrou G; Erden A; Rapsomaniki P; Terizaki M; Avgoustidis N; Repa A; Kougkas N; Bertsias G; Boumpas DT; Sidiropoulos PI
    Clin Exp Rheumatol; 2018; 36(5):806-813. PubMed ID: 29533750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis.
    Lee KE; Choi SE; Xu H; Kang JH; Park DJ; Lee SS
    Rheumatol Int; 2017 Dec; 37(12):2027-2034. PubMed ID: 28956118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.
    Kim HL; Kim D; Jang EJ; Lee MY; Song HJ; Park SY; Cho SK; Sung YK; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim J; Kim SK; Kim TH; Kim TJ; Koh E; Lee H; Lee HS; Lee J; Lee SS; Lee SW; Park SH; Shim SC; Yoo DH; Yoon BY; Bae SC; Lee EK
    Rheumatol Int; 2016 Apr; 36(4):505-13. PubMed ID: 26849891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden.
    Wallman JK; Eriksson JK; Nilsson JÅ; Olofsson T; Kristensen LE; Neovius M; Geborek P
    J Rheumatol; 2016 Jul; 43(7):1292-9. PubMed ID: 27252420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of pain score measured by a visual analog scale (PS-VAS) on the Health Assessment Questionnaire Disability Index and 28-joint Disease Activity Index with C-reactive protein in rheumatoid arthritis patients.
    Yoshii I; Chijiwa T; Sawada N
    Int J Rheum Dis; 2018 Nov; 21(11):1955-1961. PubMed ID: 30175554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
    Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
    Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical performance of rheumatoid arthritis impact of disease score: a real-life evidence from the multicenter nationwide registry BioStaR.
    Melikoglu MA; Ataman S; Bodur H; Cay HF; Capkin E; Akgul O; Cevik R; Gogus F; Kamanli A; Yurdakul FG; Gurer G; Yagci I; Rezvani A; Duruoz MT; Sunar I
    Rheumatol Int; 2021 Nov; 41(11):1971-1978. PubMed ID: 34559275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
    Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
    Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Remission or Combined Remission and Low Disease Activity in Rheumatoid Arthritis Patients in Taiwan: A Prospective Cohort Study.
    Tsai PH; Fang YF; Chen YF; Chen CC; Chiang WY; Chang CT; Huang YJ; Liou LB
    J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731049
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
    Doumen M; De Cock D; Pazmino S; Bertrand D; Joly J; Westhovens R; Verschueren P
    Arthritis Res Ther; 2021 Oct; 23(1):269. PubMed ID: 34706771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.